S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NASDAQ:CYAD - CELYAD SA/ADR Stock Price, Forecast & News

$9.93
+0.37 (+3.87 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$9.61
Now: $9.93
$10.04
50-Day Range
$9.56
MA: $10.90
$12.42
52-Week Range
$8.10
Now: $9.93
$22.99
Volume11,975 shs
Average Volume24,286 shs
Market Capitalization$138.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYAD
CUSIPN/A
Phone321-039-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.68 million
Book Value$6.65 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$138.42 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive CYAD News and Ratings via Email

Sign-up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter.


CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions

What is CELYAD SA/ADR's stock symbol?

CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD."

When is CELYAD SA/ADR's next earnings date?

CELYAD SA/ADR is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for CELYAD SA/ADR.

What price target have analysts set for CYAD?

3 analysts have issued 1-year target prices for CELYAD SA/ADR's shares. Their forecasts range from $25.00 to $43.00. On average, they expect CELYAD SA/ADR's share price to reach $34.00 in the next year. This suggests a possible upside of 242.4% from the stock's current price. View Analyst Price Targets for CELYAD SA/ADR.

What is the consensus analysts' recommendation for CELYAD SA/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CELYAD SA/ADR.

What are Wall Street analysts saying about CELYAD SA/ADR stock?

Here are some recent quotes from research analysts about CELYAD SA/ADR stock:
  • 1. According to Zacks Investment Research, "Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. " (2/11/2020)
  • 2. HC Wainwright analysts commented, "Our $48 price target is based on our probability-adjusted revenue forecasts for CYAD-01 in r/r AML, and third-line metastatic for metastatic CRC. We use the net present value of our revenue forecast through 2027, apply a 25% POS for 20% POS for 20% POS for 4x price/sales multiple. We include our year-end 2019 estimated fully diluted net cash of $1.20/share (assuming €1.00 = $1.11) to arrive at our price target. Our P/S multiple of 4x is in-line with Celyad’s peers that range between 2-5x." (8/26/2019)
  • 3. William Blair analysts commented, "We believe that the data readouts in the second half of the year will shed light into the clinical improvements with the Optimab process, allogeneic platform, and the impact of the preconditioning regimen at potentially clinically relevant doses with an eye toward selecting a Phase II (potentially registration enabling) study regimen in 2020. Celyad in June presented updated data from dose level 3 (3e9 cells given in three biweekly infusions) and initial data from cohort 10 (1e9 cells at a dense schedule of three CY AD-01 weekly infusions) of the THINK study at the European Hematology Association (EHA) 2019 meeting (EHA With CY AD-01 Dense Schedule and Preconditioning Regimens)." (8/23/2019)

Has CELYAD SA/ADR been receiving favorable news coverage?

Headlines about CYAD stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CELYAD SA/ADR earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for CELYAD SA/ADR.

Who are some of CELYAD SA/ADR's key competitors?

What other stocks do shareholders of CELYAD SA/ADR own?

Who are CELYAD SA/ADR's key executives?

CELYAD SA/ADR's management team includes the folowing people:
  • Mr. Michel E. Lussier, Co-Founder & Chairman (Age 63)
  • Mr. Filippo Joseph Petti, CEO & Interim CFO
  • Dr. Jean-Pierre Latere, Chief Operating Officer (Age 44)
  • Nicolas Van Hoecke, Director of Investor Relations & Communications
  • Mr. Philippe Dechamps, Chief Legal Officer (Age 49)

When did CELYAD SA/ADR IPO?

(CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

Who are CELYAD SA/ADR's major shareholders?

CELYAD SA/ADR's stock is owned by a number of of institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (10.19%), Victory Capital Management Inc. (10.13%), Jane Street Group LLC (0.08%) and UBS Group AG (0.02%).

Which institutional investors are buying CELYAD SA/ADR stock?

CYAD stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Jane Street Group LLC and UBS Group AG.

How do I buy shares of CELYAD SA/ADR?

Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is CELYAD SA/ADR's stock price today?

One share of CYAD stock can currently be purchased for approximately $9.93.

How big of a company is CELYAD SA/ADR?

CELYAD SA/ADR has a market capitalization of $138.42 million and generates $3.68 million in revenue each year. The company earns $-44,200,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis. View Additional Information About CELYAD SA/ADR.

What is CELYAD SA/ADR's official website?

The official website for CELYAD SA/ADR is http://www.celyad.com/.

How can I contact CELYAD SA/ADR?

CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100.


MarketBeat Community Rating for CELYAD SA/ADR (NASDAQ CYAD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: What is a stock buyback?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel